STAG2 Expression in 97 MDS Patients with Cytogenetic and Clinical Data

Immunohistochemistry and cytogenetic analysis results for 97 patients with myelodysplastic neoplasms (MDS), including 24 pediatric and 73 adult cases, plus 20 controls. It was created by Beatriz Ferreira da Silva to analyze STAG2 protein expression as a potential biomarker associated with aneuploidy and disease progression to acute myeloid leukemia.

Use Cases

• Analyze the association between reduced STAG2 expression and abnormal karyotypes, including structural alterations and aneuploidies.
• Investigate the correlation of STAG2 expression levels with specific cytogenetic features such as complex karyotypes and trisomy of chromosome 8.
• Assess STAG2 expression differences between pediatric and adult MDS patient cohorts.
• Explore the potential of STAG2 expression as a prognostic biomarker for progression from MDS to acute myeloid leukemia (AML).

Strengths

• Includes data from 97 MDS patients and 20 controls, providing a defined clinical cohort.
• Integrates multiple data types: protein expression (immunohistochemistry), cytogenetic analysis (karyotypes, aneuploidies), and patient demographics (age group).
• Results are grounded in specific findings, such as reduced STAG2 expression in 67% of MDS cases and its association with 86% of complex karyotypes.

Limitations

• Small sample size of 97 patients limits statistical power for subgroup analyses.
• Dataset scope is limited to the specific study's patient cohort and may not be generalizable to all MDS populations.
• The 15.0 KB file size suggests the data is a summary or processed table, not raw experimental data.

Provenance

Source

Beatriz Ferreira da Silva via figshare.

Collection Method

STAG2 expression analyzed by immunohistochemistry on bone marrow biopsies; cytogenetic analysis by G-banding and FISH.

Freshness

Last updated 2026-03-20.